Subscribe
Pet Food & CPG
7 min read

Amanda Rolat | Founder, Bramble

Bramble founder Amanda Rolat on building a plant-based pet food brand around health outcomes instead of ideology, why Royal Canin and Hill’s have quietly used plant protein for years, raising $4.5M for a category most investors don’t yet know how to size, and why her senior dogs are shaping the company’s next chapter.

Written by
Roy Ben-Tzvi
Published on
October 27, 2026
Amanda Rolat, Founder of Bramble

Amanda Rolat didn't set out to start a plant-based pet food company. She set out to fix her dog's allergies. That distinction, health first, ideology never, is what she argues separates Bramble from the wave of ethics-driven animal product alternatives that rode the plant-based hype cycle and largely washed out.

In this conversation, Rolat gets into how a vet nutritionist's suggestion to try tofu became a commercially viable product, why Royal Canin and Hill's have quietly been doing this for years without calling it vegan, and what it actually takes to raise $4.5M for a category that most investors don't yet know how to size.

She also talks about the pressure to expand too fast, the surprisingly warm culture of pet trade shows, and why her senior dogs — fewer teeth and all — are shaping Bramble's next chapter.

‍

Most plant-based pet brands emphasize ethics or sustainability, but Bramble focuses on health outcomes like allergies and kidney disease. What insight gave you the conviction that this positioning could support a venture-scale business rather than remain a niche lifestyle brand?

My own personal experience with my dogs, combined with my experience selling and explaining Bramble to consumers and investors. Deservedly or not, the plant-based hype has faded, leaving behind skepticism about the category's long-term strength and size. This is especially so with respect to plant-based pet food.

This was deeply frustrating to me because I, too, shared doubts about ultra-processed dry vegan pet food, which led me to start Bramble. People assumed it was just vegan pet food for vegan pet owners, but Royal Canin and Hill's have been using plant protein in their hypoallergenic lines and not marketing it as plant-based. One of my dogs needed a hypoallergenic food, so I hired a vet nutritionist to formulate something for me to cook at home, and she suggested tofu.

It worked so well for him, but there was nothing commercially available. I always saw this as a health product. The ethics and sustainability are added bonuses.

Subscribe to newsletter

Join our newsletter to stay up to date on features and releases.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

By clicking Sign Up you're confirming that you agree with our Terms and Conditions.

Pro
Keep Reading

Other Interviews

More conversations with founders, operators, and investors building the future of pet care.

Learn more
Deven Vespi | Advisor, DRV Advisory
Pet Health & Wellness
13 min read

Deven Vespi | Advisor, DRV Advisory

Clinically proven has no shared definition in pet, yet it now shapes deals as much as labels. Deven Vespi learned the trade in FDA-regulated animal health, and she explains how to check a study before you trust it or build a deal on it. She covers sample sizes, dosing gaps, why brands get blindsided by their own research, and how long published data stays an edge.

Learn more
Learn more
Meet the Founders: 3 Startups Shaping the Future of Pet Health
Pet Health & Wellness
10 min read

Meet the Founders: 3 Startups Shaping the Future of Pet Health

Pawsible Ventures took seven of more than 130 applicants into its second cohort. Three of them work very different corners of pet health. Nicole Shlomof and Gila Leibovitch of Pawp Water sell functional water to owners who already fill the bowl, Andria Beal of EpiPaws turned dolphin epigenetics research into biological-age tests for dogs and cats, and Elliot Greenwood of ChckVet sells software to vet practices that resist new tech.

Learn more
Learn more
Elizabeth Iorns | Co-Founder & CEO, Familiar Therapeutics
Pet Health & Wellness
17 min read

Elizabeth Iorns | Co-Founder & CEO, Familiar Therapeutics

Elizabeth Iorns lost her French Bulldog to a brain tumor that a published canine study suggested could be treated, but no company had taken the drug forward for dogs. Now she and Science Exchange co-founder Dan Knox license the companion animal rights to human drugs at Familiar Therapeutics: 13 programs and $5 million raised in five months, plus a pitch to pharma that pet trials validate targets faster than phase two.

Learn more
View all interviews